November 6, 2026

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 543434

National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA

Dear Sir (s),

Sub: Outcome of Board Meeting held on November 6, 2026

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Friday, November 6, 2026, inter-alia to considered and approved the following:

1. **The Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026.**
   Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026, are enclosed herewith, together with the Limited Review Report of the Statutory Auditors of the Company.
2. **Appointment of Mr. Mangesh Vaze as Senior Management Personnel**.
   Upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company approved the appointment of Mr. Mangesh Vaze as Chief Operating Officer and Senior Management Personnel of the Company effective from November 6, 2026.

Information pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, read with relevant SEBI Circular(s) are enclosed herewith. The above information will also be available on the website of the Company.

The Meeting of the Board of Directors of the Company commenced at 10:30 p.m. and concluded at 12.40 p.m.

Kindly take the above information on your records.

Thanking you,
Yours faithfully,
For Supriya Lifescience Limited

Prachi Suhas Sathe

Digitally signed by Prachi Suhas Sathe
Date: 2026.11.06 12:42:09 +05'30'

Prachi Sathe
Company Secretary & Compliance Officer

Corporate office *:* 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com

Factory *:* A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

Annexure A

Details with respect to appointment of Senior Management Personnel under Regulation 30(6) read with Para A(7) of Part A of Schedule III of the Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024:

Appointment of Mr. Mangesh Vaze as Chief Operating Officer and Senior Management Personnel of the Company:

Sr. No	Details of events that need to be provided	Information of such event(s)
1.	Reason for change viz. appointment, ~~resignation, removal, death or otherwise~~	The Board of Directors of the Company has today viz. November 6, 2026, approved the appointment of Mr. Mangesh Vaze, as Chief Operating Officer and Senior Management Personnel of the Company, with effect from November 6, 2026.
2.	Date of appointment/cessation (as applicable) and term of appointment	Date of Appointment: November 6, 2026 Term - Not Applicable
3.	Brief Profile (in case of appointment)	Mr. Vaze has completed B.E. Chemical Engineering and Executive MBA specialized in strategy, marketing, finance with approximately 34 years of professional experience in the areas of Production, Process Engineering, API Manufacturing and Operations. During his professional career, he has been associated with Zydus Lifescience Ltd., Cipla Ltd., Mylan Laboratories Ltd., Apotex Pharmachem India Pvt Ltd, Wockhardt Ltd., Orchid Chemicals & Pharmaceuticals Ltd. and Lupin Ltd. wherein he has handled responsibilities as in the fields as mentioned above.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable. Mr. Mangesh Vaze is not related to any Director of the Company.
5.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/ CML/2018/24, both dated 20 June 2018	Not Applicable.

KAKARIA AND ASSOCIATES LLP
CHARTERED ACCOUNTANTS
UJWAL K. KAKARIA B.Com.,B.L.,F.C.A.
SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.
JAIPRAKASH H. SHETHIYA B.Com., F.C.A.
AMAR J. BHANUSHALI B.Com., D.T.M., F.C.A.
VINAYAK P. BAFANA B.Com., F.C.A.

YOUR REF. :
OUR REF. :

Independent Auditor's Review Report on Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
Board of Directors of Supriya Lifescience Limited,

1. We have reviewed the accompanying statement of unaudited financial results of **Supriya Lifescience Limited** ("the Company") for the quarter ended 30th September 2026, ("the Statement"), being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing regulations")

2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting

Lotus Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri - West, Mumbai - 400 053 Tel: 022 26744670. Email: mumbai@kakariaassociates.com,
Website: www.kakariaassociates.com

KAKARIA & ASSOCIATES LLP * M. NO. 35416 MUMBAI * CHARTERED ACCOUNTANTS

matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 14th October, 2021 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For,
Kakaria and Associates LLP
Chartered Accountants.
FRN: 104558W/ W100601

KAKARIA & ASSOCIATES LLP ★ CHARTERED ACCOUNTANTS ★ M. NO. 35416 MUMBAI

CA. Ujwal K. Kakaria
Partner
Membership No. - 035416
Place: - Mumbai
Date: - 6th November, 2026
UDIN: - 26035416BXOQJW8509

SUPRIYA LIFESCIENCE LIMITED

CIN No: L51900MH2008PLC180452
207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063.
Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

(₹ In million)

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2026

Sr.No.	Particulars	Quarter ended 30-09-2026	Quarter ended 30-06-2026	Quarter ended 30-09-2025	Half Year ended 30-09-2026	Half Year ended 30-09-2025	Year ended 31-03-2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
I	Revenue from Operations	2,062.97	1,897.47	1,998.33	3,960.44	3,449.07	8,278.75
II	Other Income	22.92	26.48	27.25	49.40	53.99	114.87
III	**Total Income**	**2,085.89**	**1,923.95**	**2,025.58**	**4,009.84**	**3,503.06**	**8,393.62**
	Expenses						
	a) Cost of Materials Consumed	924.55	1,094.00	606.83	2,018.55	1,044.59	2,651.18
	b) Purchase of Stock in Trade	-	-	-	-	-	-
	c) Change in inventories of finished goods , work in progress & stock in trade.	(213.95)	(530.15)	(49.53)	(744.10)	(169.57)	(110.89)
	d. Employee benefit expenses	261.43	284.90	244.81	546.33	471.69	966.80
	e. Finance Cost	4.57	3.74	4.15	8.31	9.27	18.89
	f. Depreciation & amortisation expense	94.59	89.40	66.39	183.99	130.90	284.09
	g. Other expenditure	636.92	574.14	469.75	1,211.06	858.88	1,831.18
IV	**Total Expenses**	**1,708.11**	**1,516.03**	**1,342.40**	**3,224.14**	**2,345.76**	**5,641.25**
V	Profit/(loss) before Exceptional Items & Tax (III - IV)	377.78	407.92	683.18	785.70	1,157.30	2,752.37
VI	Exceptional Items	-	-	-	-	-	(4.58)
VII	**Profit/(loss) before Tax (V-VI)**	**377.78**	**407.92**	**683.18**	**785.70**	**1,157.30**	**2,747.79**
VIII	**Tax Expense**						
	a) Current Tax	63.87	85.13	151.58	149.00	256.93	614.33
	b) Deferred Tax	21.41	82.36	27.33	103.77	48.20	42.26
IX	**Profit/(Loss) for the period from Continuing Operations (VII-VII)**	**292.50**	**240.43**	**504.27**	**532.93**	**852.17**	**2,091.20**
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-	-	-
XIII	**Profit/(Loss) for the period (IX+XII)**	**292.50**	**240.43**	**504.27**	**532.93**	**852.17**	**2,091.20**
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	(13.70)	8.65	0.45	(5.05)	(2.42)	(1.33)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	3.45	(2.18)	(0.11)	1.27	0.61	0.34
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income (Loss)	(10.25)	6.47	0.34	(3.78)	(1.81)	(0.99)
XV	**Total Comprehensive Income for the period (XIII+XIV)**	**282.25**	**246.90**	**504.61**	**529.15**	**850.36**	**2,090.21**
XVI	Paid-up Equity Share Capital (face value ₹ 2/- each)	160.97	160.97	160.97	160.97	160.97	160.97
XVII	Other Equity						11,816.36
XVIII	Earnings per equity Share						
	(1) Basic (In ₹)	3.63	2.99	6.27	6.62	10.59	25.98
	(2) Diluted (In ₹)	3.63	2.99	6.27	6.62	10.59	25.98



Supriya Lifescience Limited

Standalone Balance Sheet as at September 30, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	September 30, 2026	March 31, 2026
ASSETS		
Non-current assets		
(a) Property, plant and equipment	7,286.08	6,833.17
(b) Right to Use Asset	48.20	45.23
(c) Capital Work in progress	71.27	355.48
(d) Intangible Assets	11.79	13.12
(e) Financial Assets		
(i) Investments	1,066.39	985.23
(ii) Loans and Advances	-	-
(f) Other Non- Current Assets	27.92	15.81
Total Non-current assets	**8,511.65**	**8,248.04**
Current assets		
(a) Inventories	2,651.68	1,595.97
(b) Financial Assets		
(i) Loans and Advances	5.07	5.69
(ii) Trade receivables	1,255.80	2,194.48
(iii) Cash and cash equivalents	410.21	274.80
(iv) Bank balances other than (iii) above	349.10	100.65
(v) Other Financial Assets	-	-
(c) Other current assets	1,033.30	1,151.44
Total Current Assets	**5,705.16**	**5,323.03**
TOTAL ASSETS	**14,216.81**	**13,571.07**
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity share capital	160.97	160.97
(b) Other equity	12,265.03	11,816.36
Total Equity	**12,426.00**	**11,977.33**
LIABILITIES		
Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Lease Liabilities	54.85	51.89
(iii) Other financial liabilities	-	-
(b) Provisions	15.45	18.97
(c) Deferred tax Liabilities	416.20	312.44
Total Non-Current Liabilities	**486.50**	**383.30**
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	-	-
(ii) Lease liabilities	3.18	2.46
(iii) Trade payables		
- Micro Enterprises and Small Enterprises	429.31	170.01
- Other than Micro Enterprises and Small Enterprises	641.78	938.46
(iii) Other financial liabilities	106.89	20.40
(b) Provisions	9.38	16.71
(c) Other current liabilities	113.77	62.40
Total Current Liabilities	**1,304.31**	**1,210.44**
TOTAL EQUITY AND LIABILITIES	**14,216.81**	**13,571.07**


SUPRIYA LIFESCIENCE LTD. MUMBAI

Supriya Lifescience Limited

Cash flow statement for the period ended September 30, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	September 30, 2026	March 31, 2026
A CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	**785.70**	**2,747.79**
Adjustments for		
Depreciation and Amortization	183.99	284.09
Interest Income (Net of Expenses)	(38.87)	(94.54)
Dividend Received	-	(0.00)
Employee Benefit	(15.90)	9.24
Loss on Sale of fixed Assets	-	0.09
Modification of Lease	-	-
Operating profit before working capital changes	**914.92**	**2,946.67**
Adjustments for movement in working capital		
Adjustments for (increase)/ decrease in operating assets		
Trade Receivables	938.69	(850.85)
Inventories	(1,055.71)	(412.48)
Other Non Current & Current Assets	(142.42)	(39.72)
Other Non Current & Current Financial Assets	-	7.11
Loans and Advances	0.62	3.58
	(258.82)	**(1,292.36)**
Adjustments for increase/ (decrease) in operating liabilities		
Trade payables	(37.38)	363.01
Other Non Current & Current Financial Liabilities	86.49	2.80
Other Non Current & Current liabilities	51.36	(31.34)
	100.47	**334.47**
(Income tax paid)/net of refund	(147.73)	(613.99)
Net Cash generated from Operating Activities (A)	**608.84**	**1,374.79**
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(354.34)	(1,522.35)
(Purchase)/ Sale of Investments	(81.16)	(352.82)
Interest Income	47.18	113.43
Dividend Received	-	0.00
Net Cash generated/(outflow) from Investing Activities (B)	**(388.32)**	**(1,761.74)**
C CASH FLOW FROM FINANCING ACTIVITIES		
Increase/(Decrease) in Long term borrowings	-	-
Increase/(Decrease) in Short term borrowing	-	-
Finance Cost	(8.31)	(18.89)
Dividend Paid	(80.48)	(80.48)
Repayment of Lease liability	3.68	0.55
Net Cash generated from Financing Activities (C)	**(85.11)**	**(98.82)**
Net Increase/(Decrease) in Cash and Cash equivalents (A+B+C)	135.41	(485.77)
Cash and Cash Equivalents at the end of previous period	274.80	760.57
Cash and Cash Equivalents as at the end of the reporting period	**410.21**	**274.80**



Notes:-

1. The above standalone unaudited financial results of the Company for the half year ended and quarter ended September 30, 2026 have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as amended.

2. The above standalone unaudited financial results of the Company for the half year ended and quarter ended September 30, 2026 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on November 06, 2026.

3. The material intended for export in Quarter 1 of FY 2026-27 was detained by Customs during transit. After obtaining clearance and release from Customs, the material was successfully exported on October 02, 2026.

4. The company does not have any subsidiary/associate/joint venture company as on September 30, 2026.

5. The figures of the previous periods have been regrouped wherever necessary to confirm to the current period presentation.

For Supriya Lifescience Limited

SUPRIYA LIFESCIENCE LTD. MUMBAI

Place :- Mumbai
Date :- November 06, 2026

Dr. Saloni Wagh
Managing Director
DIN: 08491410